Second Quarter 2025 Financial Results - Total revenue reached $325.7 million, a 41% increase compared to the second quarter of 2024[32] - Royalty revenue increased by 65% to $205.6 million[32] - Net income was $165.2 million, a 77% increase year-over-year[32] - Adjusted EBITDA was $225.5 million, a 65% increase compared to the same period last year[32] - GAAP diluted EPS increased by 85% to $1.33, while Non-GAAP diluted EPS increased by 69% to $1.54[32] Full Year 2025 Guidance - Total revenue is projected to be between $1.275 billion and $1.355 billion, representing a 26-33% increase[6] - Royalty revenue is expected to be between $825 million and $860 million, a 44-51% increase[6] - Adjusted EBITDA is guided to be between $865 million and $915 million, a 37-45% increase[6] - Non-GAAP diluted EPS is projected to be between $6.00 and $6.40, a 42-51% increase[6] Share Repurchase Program - The company completed a $250 million accelerated share repurchase program[6] - A new $250 million share repurchase program was announced[6]

Financial Performance - Q1 2025 - Total revenue reached $265 million, a 35% increase compared to the same period last year[9] - Royalty revenue increased by 39% to $168 million[9] - GAAP net income was $118 million, a 54% increase[9] - GAAP diluted EPS increased by 55% to $0.93, while non-GAAP diluted EPS increased by 41% to $1.11[9] - Adjusted EBITDA increased by 40% to $162 million[9] Key Products & Growth Drivers - DARZALEX® SC U S market share is approximately 95%[11] - DARZALEX® sales reached $3.2 billion in Q1 2025, a 22% year-over-year increase[12] - Phesgo® sales are projected to reach $3.3 billion in 2028[14], with Q1 2025 revenue at approximately $675 million, a 52% year-over-year increase[15] - VYVGART® & VYVGART® Hytrulo SC are projected for blockbuster growth to approximately $7 billion in 2028[18] Financial Outlook & Capital Allocation - The company announced a new $250 million share repurchase program[10, 37] - The company projects approximately $1 billion of royalty revenue in 2027[31] - Total revenue for 2025 is guided between $1200 million and $1280 million[40]